CN115087658B - 具有诱导brd4蛋白质分解作用的磺酰胺或亚磺酰胺化合物及其药物用途 - Google Patents

具有诱导brd4蛋白质分解作用的磺酰胺或亚磺酰胺化合物及其药物用途 Download PDF

Info

Publication number
CN115087658B
CN115087658B CN202180012524.0A CN202180012524A CN115087658B CN 115087658 B CN115087658 B CN 115087658B CN 202180012524 A CN202180012524 A CN 202180012524A CN 115087658 B CN115087658 B CN 115087658B
Authority
CN
China
Prior art keywords
group
compound
cyano
cancer
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180012524.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115087658A (zh
Inventor
大场清美
丹羽靖哉
松平铁二
浜田真以子
山崎龙太
伊吹达也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=77199607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115087658(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN115087658A publication Critical patent/CN115087658A/zh
Application granted granted Critical
Publication of CN115087658B publication Critical patent/CN115087658B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180012524.0A 2020-02-06 2021-02-05 具有诱导brd4蛋白质分解作用的磺酰胺或亚磺酰胺化合物及其药物用途 Active CN115087658B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020019227 2020-02-06
JP2020-019227 2020-02-06
PCT/JP2021/004231 WO2021157684A1 (ja) 2020-02-06 2021-02-05 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途

Publications (2)

Publication Number Publication Date
CN115087658A CN115087658A (zh) 2022-09-20
CN115087658B true CN115087658B (zh) 2025-02-28

Family

ID=77199607

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180012524.0A Active CN115087658B (zh) 2020-02-06 2021-02-05 具有诱导brd4蛋白质分解作用的磺酰胺或亚磺酰胺化合物及其药物用途

Country Status (14)

Country Link
US (3) US12102641B2 (https=)
EP (1) EP4105220A4 (https=)
JP (3) JP7419406B2 (https=)
KR (1) KR20220139912A (https=)
CN (1) CN115087658B (https=)
AR (1) AR121275A1 (https=)
AU (1) AU2021215623A1 (https=)
BR (1) BR112022014889A2 (https=)
CA (1) CA3168824C (https=)
IL (1) IL295041A (https=)
MX (1) MX2022009700A (https=)
TW (1) TWI887352B (https=)
WO (1) WO2021157684A1 (https=)
ZA (1) ZA202209896B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7419406B2 (ja) 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途
JP2022123408A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123894A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP2022123407A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123893A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP7852736B2 (ja) * 2022-10-28 2026-04-28 株式会社村田製作所 電子部品および電子部品の実装構造
WO2024251876A1 (en) * 2023-06-07 2024-12-12 KRæFTENS BEKæMPELSE PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS
CN118359621B (zh) * 2024-04-16 2025-05-16 上海陶术生物科技股份有限公司 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体
CN120865239B (zh) * 2025-09-25 2025-12-12 深圳大学 基于苯并咪唑融合共价弹头的降解剂及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118851A1 (en) * 2017-12-14 2019-06-20 Dana-Farber Cancer Institute, Inc. Small molecule degraders that recruit dcaft15
WO2020009176A1 (ja) * 2018-07-04 2020-01-09 田辺三菱製薬株式会社 Ｂｅｔ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
JP2801500B2 (ja) 1993-07-02 1998-09-21 株式会社トクヤマ Ｎ−アルコキシカルボニルアミノ酸の製造方法
CN1109037C (zh) 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN108727380A (zh) * 2017-04-13 2018-11-02 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
CN109503618A (zh) * 2017-09-14 2019-03-22 成都海创药业有限公司 一种brd4抑制剂
US11629152B2 (en) * 2018-03-30 2023-04-18 Kyowa Kirin Co., Ltd. Compound with anticancer activity
JP7140273B2 (ja) 2019-04-09 2022-09-21 株式会社村田製作所 電池
JP7419406B2 (ja) * 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118851A1 (en) * 2017-12-14 2019-06-20 Dana-Farber Cancer Institute, Inc. Small molecule degraders that recruit dcaft15
WO2020009176A1 (ja) * 2018-07-04 2020-01-09 田辺三菱製薬株式会社 Ｂｅｔ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途

Also Published As

Publication number Publication date
KR20220139912A (ko) 2022-10-17
US20230146717A1 (en) 2023-05-11
TWI887352B (zh) 2025-06-21
ZA202209896B (en) 2025-12-17
MX2022009700A (es) 2022-09-07
US12102641B2 (en) 2024-10-01
WO2021157684A1 (ja) 2021-08-12
EP4105220A4 (en) 2024-02-21
IL295041A (en) 2022-09-01
AU2021215623A1 (en) 2022-08-25
CA3168824C (en) 2024-10-22
TW202140498A (zh) 2021-11-01
US20230364105A1 (en) 2023-11-16
AR121275A1 (es) 2022-05-04
JPWO2021157684A1 (https=) 2021-08-12
JP2024041888A (ja) 2024-03-27
JP7419406B2 (ja) 2024-01-22
CA3168824A1 (en) 2021-08-12
EP4105220A1 (en) 2022-12-21
JP2025122015A (ja) 2025-08-20
CN115087658A (zh) 2022-09-20
US11890288B2 (en) 2024-02-06
JP7681737B2 (ja) 2025-05-22
BR112022014889A2 (pt) 2022-09-20
US20240390387A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
CN115087658B (zh) 具有诱导brd4蛋白质分解作用的磺酰胺或亚磺酰胺化合物及其药物用途
CN112543764B (zh) 具有bet蛋白水解诱导作用的酰胺化合物及其医药应用
US9738630B2 (en) Inhibitors of lysine methyl transferase
CN111051300B (zh) 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
AU2017226005A1 (en) Inhibitors of WDR5 protein-protein binding
US20170166555A1 (en) Functionalised and substituted indoles as anti-cancer agents
CN112778302A (zh) 一种kras g12c抑制剂化合物及其用途
JP7614145B2 (ja) Ｂｒｄ４蛋白質分解誘導剤を含む医薬
WO2020253711A1 (zh) 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
KR20090082486A (ko) 항암성 약물로서 ｃ12-ｃ13 위치에서 개질된 에포틸론 유사체
CN109476649B (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
RU2830112C1 (ru) Соединение сульфонамида или сульфинамида, обладающее эффектом индуцирования деградации белка brd4, и его применение в медицине
WO2017181974A1 (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
HK40080729A (en) Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof
CN119264055A (zh) 一种wdr5抑制剂及其制备方法和用途
WO2022166990A1 (zh) 用于抗肿瘤的药物组合
WO2017181973A1 (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
JP2026508759A (ja) ヒドラジド、ヒドラジン、及びヒドロキサム酸官能基を含有するｓｔｉｎｇアゴニスト
WO2025198588A1 (en) Preparation of compound and crystalline forms thereof
CN102249958B (zh) 苯甲酰氨类组蛋白去乙酰化酶抑制剂
WO2020180876A1 (en) Orai channel inhibitors
CN102321034A (zh) 硫代苯二氮卓类化合物及其作为药物的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant